Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 EPIDEMIOLOGY BASED MODEL
2.2.11 VENDOR SHARE ANALYSIS
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 REGULATORY SCENARIO
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 RELAPSING FORM
10.3 MONOPHASIC FORM
11 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY ANTIBODIES
11.1 OVERVIEW
11.2 ANTI-AQP4+ VARIANTS
11.3 ANTI-MOG+ VARIANTS
12 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY TREATEMT
12.1 OVERVIEW
12.2 DRUG
12.2.1 MONOCLONAL ANTIBODY
12.2.1.1. ECULIZUMAB
12.2.1.2. INEBILIZUMAB
12.2.1.3. SATRALIZUMAB
12.2.1.4. OTHER
12.2.2 IMMUNOSUPPRESSIVE
12.2.2.1. AZATHIOPRINE
12.2.2.2. MYCOPHENOLATE
12.2.2.3. RITUXIMAB
12.2.2.4. METHOTREXATE
12.2.2.5. MITOXANTRONE
12.2.2.6. ECULIZUMAB
12.2.2.7. TOCILIZUMAB
12.2.2.8. OTHER
12.2.2.9. CORTICOSTEROIDS
12.2.2.9.1. METHYLPREDNISOLONE
12.2.2.9.2. PREDNISONE
12.2.2.9.3. OTHERS
12.2.3 ANTI-EPILEPTIC MEDICATIONS
12.2.3.1. GABAPENTIN
12.2.3.2. CARBAMAZEPINE
12.2.3.3. OTHERS
12.2.4 ANTI-SPASMODICS
12.2.4.1. BACLOFEN
12.2.4.2. TIZANIDINE
12.2.4.3. OTHERS
12.2.5 ANTI-DEPRESSANTS
12.2.5.1. AMITRIPTYLINE
12.2.5.2. DULOXETINE
12.2.5.3. OTHERS
12.2.6 ANALGESICS
12.2.6.1. TRAMADOL
12.2.6.2. OPIATES
12.2.6.3. OTHERS
12.2.7 OTHERS
12.3 PLASMA THERAPY
12.4 DIAGNOSIS
12.4.1 MRI
12.4.2 ANTIBODY TEST
12.4.3 LUMBAR PUNCTURE (SPINAL TAP)
12.4.4 STIMULI RESPONSE TEST
12.4.5 OTHERS
12.5 OTHER
13 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 SOLIRIS
13.2.2 UPLIZNA
13.2.3 ENSPRYNG
13.2.4 OTHER
13.3 GENERICS
14 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY SYMPTOMS
14.1 OVERVIEW
14.2 OPTIC NEURITIS
14.3 ACUTE MYELITIS
14.4 AREA POSTREMA SYNDROME
14.5 ACUTE BRAINSTEM SYNDROME
14.6 SYMPTOMATIC NARCOLEPSY/ACUTE DIENCEPHALIC CLINICAL SYNDROME
14.7 SYMPTOMATIC CEREBRAL SYNDROME WITH NSMOD-TYPICAL BRAIN LESION
14.8 OTHERS
15 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY POPULATION TYPE
15.1 OVERVIEW
15.2 PEDIATRIC
15.3 ADULTS
16 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY ROUTE OF ADMINISTRATION
16.1 OVERVIEW
16.2 ORAL
16.2.1 TABLETS
16.2.2 SUSPENSION
16.2.3 OTHERS
16.3 PARENTERAL
16.3.1 INTRAVENOUS
16.3.2 SUBCUTANEOUS
16.3.3 OTHERS
16.4 OTHERS
17 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACIES
18.3 RETAIL PHARMACIES
18.4 ONLINE PHARMACIES
18.5 OTHERS
19 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, BY GEOGRAPHY
GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
20.1 NORTH AMERICA
20.1.1 U.S.
20.1.2 CANADA
20.1.3 MEXICO
20.2 EUROPE
20.2.1 GERMANY
20.2.2 U.K.
20.2.3 ITALY
20.2.4 FRANCE
20.2.5 SPAIN
20.2.6 RUSSIA
20.2.7 SWITZERLAND
20.2.8 TURKEY
20.2.9 BELGIUM
20.2.10 NETHERLANDS
20.2.11 DENMARK
20.2.12 SWEDEN
20.2.13 POLAND
20.2.14 NORWAY
20.2.15 FINLAND
20.2.16 REST OF EUROPE
20.3 ASIA-PACIFIC
20.3.1 JAPAN
20.3.2 CHINA
20.3.3 SOUTH KOREA
20.3.4 INDIA
20.3.5 SINGAPORE
20.3.6 THAILAND
20.3.7 INDONESIA
20.3.8 MALAYSIA
20.3.9 PHILIPPINES
20.3.10 AUSTRALIA
20.3.11 NEW ZEALAND
20.3.12 VIETNAM
20.3.13 TAIWAN
20.3.14 REST OF ASIA-PACIFIC
20.4 SOUTH AMERICA
20.4.1 BRAZIL
20.4.2 ARGENTINA
20.4.3 REST OF SOUTH AMERICA
20.5 MIDDLE EAST AND AFRICA
20.5.1 SOUTH AFRICA
20.5.2 EGYPT
20.5.3 BAHRAIN
20.5.4 UNITED ARAB EMIRATES
20.5.5 KUWAIT
20.5.6 OMAN
20.5.7 QATAR
20.5.8 SAUDI ARABIA
20.5.9 REST OF MEA
20.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
21 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) MARKET, COMPANY PROFILE
22.1 ALEXION PHARMACEUTICALS, INC.
22.1.1 COMPANY OVERVIEW
22.1.2 REVENUE ANALYSIS
22.1.3 GEOGRAPHIC PRESENCE
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 VIELA BIO.( HORIZON THERAPEUTICS PLC)
22.2.1 COMPANY OVERVIEW
22.2.2 REVENUE ANALYSIS
22.2.3 GEOGRAPHIC PRESENCE
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 F. HOFFMANN-LA ROCHE LTD
22.3.1 COMPANY OVERVIEW
22.3.2 REVENUE ANALYSIS
22.3.3 GEOGRAPHIC PRESENCE
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 AMNEAL PHARMACEUTICALS LLC
22.4.1 COMPANY OVERVIEW
22.4.2 REVENUE ANALYSIS
22.4.3 GEOGRAPHIC PRESENCE
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 ZYDUS PHARMACEUTICALS, INC.
22.5.1 COMPANY OVERVIEW
22.5.2 REVENUE ANALYSIS
22.5.3 GEOGRAPHIC PRESENCE
22.5.4 PRODUCT PORTFOLIO
22.5.5 RECENT DEVELOPMENTS
22.6 FRESENIUS KABI USA
22.6.1 COMPANY OVERVIEW
22.6.2 REVENUE ANALYSIS
22.6.3 GEOGRAPHIC PRESENCE
22.6.4 PRODUCT PORTFOLIO
22.6.5 RECENT DEVELOPMENTS
22.7 CHORD THERAPEUTICS SA
22.7.1 COMPANY OVERVIEW
22.7.2 REVENUE ANALYSIS
22.7.3 GEOGRAPHIC PRESENCE
22.7.4 PRODUCT PORTFOLIO
22.7.5 RECENT DEVELOPMENTS
22.8 ACCORD-HEALTHCARE
22.8.1 COMPANY OVERVIEW
22.8.2 REVENUE ANALYSIS
22.8.3 GEOGRAPHIC PRESENCE
22.8.4 PRODUCT PORTFOLIO
22.8.5 RECENT DEVELOPMENTS
22.9 GENENTECH INC
22.9.1 COMPANY OVERVIEW
22.9.2 REVENUE ANALYSIS
22.9.3 GEOGRAPHIC PRESENCE
22.9.4 PRODUCT PORTFOLIO
22.9.5 RECENT DEVELOPMENTS
22.1 HORIZON THERAPEUTICS PLC
22.10.1 COMPANY OVERVIEW
22.10.2 REVENUE ANALYSIS
22.10.3 GEOGRAPHIC PRESENCE
22.10.4 PRODUCT PORTFOLIO
22.10.5 RECENT DEVELOPMENTS
22.11 MYLAN N.V.
22.11.1 COMPANY OVERVIEW
22.11.2 REVENUE ANALYSIS
22.11.3 GEOGRAPHIC PRESENCE
22.11.4 PRODUCT PORTFOLIO
22.11.5 RECENT DEVELOPMENTS
22.12 ASPEN PHARAMACRE PYT LTD
22.12.1 COMPANY OVERVIEW
22.12.2 REVENUE ANALYSIS
22.12.3 GEOGRAPHIC PRESENCE
22.12.4 PRODUCT PORTFOLIO
22.12.5 RECENT DEVELOPMENTS
22.13 SANIS HEALTHCARE INC
22.13.1 COMPANY OVERVIEW
22.13.2 REVENUE ANALYSIS
22.13.3 GEOGRAPHIC PRESENCE
22.13.4 PRODUCT PORTFOLIO
22.13.5 RECENT DEVELOPMENTS
22.14 AMGEN INC
22.14.1 COMPANY OVERVIEW
22.14.2 REVENUE ANALYSIS
22.14.3 GEOGRAPHIC PRESENCE
22.14.4 PRODUCT PORTFOLIO
22.14.5 RECENT DEVELOPMENTS
22.15 TEVA PHARMACEUTICAL INDUSTRIES LTD.
22.15.1 COMPANY OVERVIEW
22.15.2 REVENUE ANALYSIS
22.15.3 GEOGRAPHIC PRESENCE
22.15.4 PRODUCT PORTFOLIO
22.15.5 RECENT DEVELOPMENTS
22.16 PFIZER INC.
22.16.1 COMPANY OVERVIEW
22.16.2 REVENUE ANALYSIS
22.16.3 GEOGRAPHIC PRESENCE
22.16.4 PRODUCT PORTFOLIO
22.16.5 RECENT DEVELOPMENTS
22.17 GLAXOSMITHKLINE PLC
22.17.1 COMPANY OVERVIEW
22.17.2 REVENUE ANALYSIS
22.17.3 GEOGRAPHIC PRESENCE
22.17.4 PRODUCT PORTFOLIO
22.17.5 RECENT DEVELOPMENTS
22.18 NOVARTIS AG
22.18.1 COMPANY OVERVIEW
22.18.2 REVENUE ANALYSIS
22.18.3 GEOGRAPHIC PRESENCE
22.18.4 PRODUCT PORTFOLIO
22.18.5 RECENT DEVELOPMENTS
22.19 APOTEX INC.
22.19.1 COMPANY OVERVIEW
22.19.2 REVENUE ANALYSIS
22.19.3 GEOGRAPHIC PRESENCE
22.19.4 PRODUCT PORTFOLIO
22.19.5 RECENT DEVELOPMENTS
22.2 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.20.1 COMPANY OVERVIEW
22.20.2 REVENUE ANALYSIS
22.20.3 GEOGRAPHIC PRESENCE
22.20.4 PRODUCT PORTFOLIO
22.20.5 RECENT DEVELOPMENTS
22.21 ANATARES PHARMA
22.21.1 COMPANY OVERVIEW
22.21.2 REVENUE ANALYSIS
22.21.3 GEOGRAPHIC PRESENCE
22.21.4 PRODUCT PORTFOLIO
22.21.5 RECENT DEVELOPMENTS
22.22 LUPIN
22.22.1 THE COMPANY OVERVIEW
22.22.2 REVENUE ANALYSIS
22.22.3 GEOGRAPHIC PRESENCE
22.22.4 PRODUCT PORTFOLIO
22.22.5 RECENT DEVELOPMENTS
22.23 HIKMA PHARAMACEUTICALS PLC
22.23.1 THE COMPANY OVERVIEW
22.23.2 REVENUE ANALYSIS
22.23.3 GEOGRAPHIC PRESENCE
22.23.4 PRODUCT PORTFOLIO
22.23.5 RECENT DEVELOPMENTS
22.24 STRIDES PHARMA INC
22.24.1 THE COMPANY OVERVIEW
22.24.2 REVENUE ANALYSIS
22.24.3 GEOGRAPHIC PRESENCE
22.24.4 PRODUCT PORTFOLIO
22.24.5 RECENT DEVELOPMENTS
22.25 SEBELA PHARAMACEUTICALS
22.25.1 THE COMPANY OVERVIEW
22.25.2 REVENUE ANALYSIS
22.25.3 GEOGRAPHIC PRESENCE
22.25.4 PRODUCT PORTFOLIO
22.25.5 RECENT DEVELOPMENTS
22.26 CONCORD BIOTECH
22.26.1 THE COMPANY OVERVIEW
22.26.2 REVENUE ANALYSIS
22.26.3 GEOGRAPHIC PRESENCE
22.26.4 PRODUCT PORTFOLIO
22.26.5 RECENT DEVELOPMENTS
22.27 JUBILANT CADISTA PHARMACEUTICALS INC
22.27.1 THE COMPANY OVERVIEW
22.27.2 REVENUE ANALYSIS
22.27.3 GEOGRAPHIC PRESENCE
22.27.4 PRODUCT PORTFOLIO
22.27.5 RECENT DEVELOPMENTS
*NOTE: COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
23 RELATED REPORTS
24 CONCLUSION
25 QUESTIONNAIRE
26 ABOUT DATA BRIDGE MARKET RESEARCH
